权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Rapid swab-based point-of-care antigen testing assay proof-of-concept for the detection of SARS-CoV-2

基于拭子的快速护理点抗原检测分析用于检测 SARS-CoV-2 的概念验证

基本信息

批准号：
63048
负责人：
金额：
$ 8.77万
依托单位：
ADAPTIVE DIAGNOSTICS LIMITED
依托单位国家：
英国
项目类别：
Feasibility Studies
财政年份：
2020
资助国家：
英国
起止时间：
2020 至无数据
项目状态：
已结题

来源：
https://gtr.ukri.org/projects?ref=63048
关键词：
Rapid swab based point care

项目摘要

The COVID-19 pandemic has had a direct effect on the livelihoods of millions here at home in the UK. Unfortunately, the restrictions set on our daily lives will persist until a coronavirus test is widely adopted. Adaptive Diagnostics have made it our mission to create a cheap, rapid and accurate saliva-based coronavirus test that can be used by all healthcare workers to quickly screen and identify those patients who are positive or negative for the disease. We will do this by detecting a distinct molecule present on the virus's surface with a novel biosensor that we are developing. This will give the user of our test a simple and reliable visual readout if the tested patient is positive for the virus. In doing so we hope to help benefit people everywhere. The technology we are developing can also be applied to other diseases, synergising with other aspects of our overall business strategy, ensuring we are best prepared to fight any future outbreaks, and bringing adaptivity to diagnostics. We aim to: * Increase the rate and ease at which people can be screened for infectious disease like COVID-19 * Reduce the risks and strains on frontline healthcare staff and centralised laboratories * Provide a novel and alternative screening method to those that are currently available in the diagnostic market

COVID-19大流行对英国数百万人的生计产生了直接影响。不幸的是，在冠状病毒检测被广泛采用之前，对我们日常生活的限制将持续存在。Adaptive Diagnostics的使命是创建一种廉价、快速和准确的唾液冠状病毒检测方法，所有医护人员都可以使用这种方法快速筛查和识别那些对该疾病呈阳性或阴性的患者。我们将通过我们正在开发的一种新型生物传感器检测病毒表面的一种独特分子来实现这一目标。这将为我们的测试用户提供一个简单而可靠的视觉读数，如果测试患者对病毒呈阳性。通过这样做，我们希望能够帮助世界各地的人们。我们正在开发的技术也可以应用于其他疾病，与我们整体业务战略的其他方面协同作用，确保我们为应对未来的任何疫情做好最充分的准备，并为诊断带来适应性。我们的目标是：* 提高人们接受COVID-19等传染病筛查的速度和难度 * 降低一线医护人员和中央实验室的风险和压力 * 为诊断市场上现有的筛查方法提供一种新的替代方法